U.S. researchers have shown that blocking S100 calcium binding protein A9 could prevent thrombosis without increasing the risk of bleeding. The findings may hand a new indication to at least two companies-InflammatoRx and Active Biotech-that are developing S100A9 inhibitors for other indications.